Pyridostigmine Bromide Tablet, Extended Release
Product Images NDC 60846-559

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Pyridostigmine Bromide (NDC 60846-559). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amneal Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Pyridostigmine Bromide Extended Release Tablets 1)

FDA Label Image

Figure 1 (Pyridostigmine Bromide Extended Release Tablets 2)

FDA Label Image

Bag Label (Pyridostigmine Bromide Extended Release Tablets 3)

This is a description of Pyridostigmine Bromide Extended-Release Tablets, each containing 105 mg of pyridostigmine bromide. They are pre-treatment tablets for the soman nerve agent. Each pack consists of 10 blisters with 7 tablets. It is recommended to discard the contents 3 months after opening the mylar bag. The tablets should be stored at 20° to 25°C with excursions permitted between 15° to 30°C or refrigerated between 2° and 8°C. Produced by Amneal Pharmaceuticals LLC in Bridgewater, NJ.*

FDA Label Image

Carton (Pyridostigmine Bromide Extended Release Tablets 4)

FDA Label Image

Blister (Pyridostigmine Bromide Extended Release Tablets 5)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.